• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Merge to acquire Interpra Medical Imaging

Article

Merge Technologies has signed a letter of intent to acquire Interpra Medical Imaging, a Toronto, Ontario-based developer of Java-based clinical workflow and information management software. Merge plans to offer Interpra’s products directly to end

Merge Technologies has signed a letter of intent to acquire Interpra Medical Imaging, a Toronto, Ontario-based developer of Java-based clinical workflow and information management software. Merge plans to offer Interpra’s products directly to end users as well as through its OEM/VAR channels. Interpra president and chief medical officer Dr. Stephen Herman will stay on as Merge’s chief medical officer.

The stock-for-stock transaction is expected to be completed by the end of August, subject to the execution of a definitive agreement, completion of due diligence, regulatory approvals, and closing conditions. Interpra shareholders would receive 420,000 shares of Merge stock, along with an equal number of put options exercisable in five years for $4.50 each. Merge’s stock closed at $1.44 per share on July 27.

In other Merge news, the Milwaukee-based company posted a revenue increase of 47% during its second quarter (end-June). Revenues were $2.8 million, compared with $1.9 million for the same period in 1998. Merge recorded a net loss of $584,000, compared with a net loss of $683,000 last year. Merge’s results were below analysts’ expectations, however.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.